Xencor Financial Results
Xencor reported financial results for the third quarter ended September 30, 2026, highlighting clinical progress for its lead bispecific antibody XmAb819 in renal cell carcinoma. The company ended the quarter with $412.4 million in cash and equivalents, providing a projected runway into 2028.
“Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a monotherapy and in combination with anti-PD(L)1 are underway, with evaluation of XmAb819 in additional ENPP3-positive tumor types also ongoing.”
Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor